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Abstract
Background Sirtuin is a member of the nicotinamide
adenine dinucleotide (NAD)-dependent deacetylases, and
has been reported to play a pivotal role in energy expen-
diture, mitochondrial function and pathogenesis of meta-
bolic diseases, including aging kidneys. In this study, we
focused on the genes encoding sirtuin families, and
examined the association between single nucleotide poly-
morphisms (SNPs) within genes encoding sirtuin families
and diabetic nephropathy.
Methods We examined 52 SNPs within the SIRT genes
(11 in SIRT1,7i nSIRT2,1 4i nSIRT3,7i nSIRT4,9i n
SIRT5, and 4 in SIRT6) in 3 independent Japanese popu-
lations with type 2 diabetes (study 1: 747 cases (overt
proteinuria), 557 controls; study 2: 455 cases (overt pro-
teinuria) and 965 controls; study 3: 300 cases (end-stage
renal disease) and 218 controls). The associations between
these SNPs were analyzed by the Cochran–Armitage trend
test, and results of the 3 studies were combined with a
meta-analysis. We further examined an independent cohort
(195 proteinuria cases and 264 controls) for validation of
the original association.
Results We identiﬁed 4 SNPs in SIRT1 that were nomi-
nally associated with diabetic nephropathy (P\0.05), and
subsequent haplotype analysis revealed that a haplotype
consisting of the 11 SNPs within SIRT1 locus had a
stronger association (P = 0.0028).
Conclusion These results indicate that SIRT1 may play a
role in susceptibility to diabetic nephropathy in Japanese
subjects with type 2 diabetes.
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Diabetic nephropathy is a serious microvascular compli-
cation of diabetes, and is a leading cause of end-stage renal
disease in Western countries [1] and in Japan [2]. The
escalating prevalence and limitation of currently available
therapeutic options highlight the need for a more accurate
understanding of the pathogenesis of diabetic nephropathy.
Several environmental factors, such as medication, daily
energy consumptions, and daily sodium intake, are likely to
cooperate with genetic factors to contribute to its devel-
opment and progression [3, 4]; however, the precise
mechanism for this contribution is unknown. Krolewski
et al. [5] reported that the cumulative incidence of diabetic
retinopathy increased linearly with duration of diabetes,
whereas the occurrence of nephropathy was almost none
after 20–25 years of diabetes duration, and only a modest
number of individuals with diabetes (*30%) developed
diabetic nephropathy. Familial clustering of diabetic
nephropathy was also reported in both type 1 [4] and type 2
diabetes [6]; thus, the involvement of genetic factors in the
development of diabetic nephropathy is strongly suggested.
Both candidate gene approaches and genome-wide linkage
analyses have suggested several candidate genes with a
potential impact on diabetic nephropathy. These ﬁndings,
however, have not been robustly replicated and many genes
responsible for susceptibility to diabetic nephropathy
remain to be identiﬁed. To identify loci involved in sus-
ceptibility to common diseases, we initiated the ﬁrst round
of a genome-wide association study (GWAS) using
100,000 single nucleotide polymorphisms (SNPs) from a
Japanese SNP database (JSNP: http://snp.ims.u-tokyo.ac.
jp/index_ja.html). Through this project, we have previously
identiﬁed genes encoding solute carrier family 12 (sodium/
chloride) member 3 (SLC12A3, MIM 600968, Online
Mendelian Inheritance in Man: http://www.ncbi.nlm.nih.
gov/omim)[ 7]; engulfment and cell motility 1 (ELMO1,
MIM 606420) [8]; neurocalcin d (NCALD, MIM 606722)
[9]; and acetyl-coenzyme A carboxylase beta gene
(ACACB, MIM: 601557) [10] as being associated with
susceptibility to diabetic nephropathy. The association
between ELMO1 or ACACB and diabetic nephropathy has
been conﬁrmed in different ethnic populations [11–13].
The GWAS for diabetic nephropathy using European
American populations (the Genetics of Kidneys in Diabetes
(GoKinD) collection) led to the identiﬁcation of 4 distinct
loci as novel candidate loci for susceptibility to diabetic
nephropathy in European American subjects with type 1
diabetes [14]: the CPVL/CHN2 locus on chromosome 7,
the FRMD3 locus on chromosome 9, the CARS locus on
chromosome 11, and a locus near IRS2 on chromosome 13.
Among those 4 loci, only one locus (near IRS2 in chro-
mosome 13) could be replicated in Japanese subjects with
type 2 diabetes [15]. Although these loci are considered as
convincing susceptibility loci for diabetic nephropathy
across different ethnic groups, a considerable number of
susceptibility genes for diabetic nephropathy still remain to
be identiﬁed.
Sirtuins, the silent information regulator-2 (SIR2) fam-
ily, is a member of NAD-dependent deacetylases, and the
sir2 gene was originally identiﬁed as a gene affecting the
malting ability of yeast. Mammalian sirtuins consist of
seven members, SIRT1–SIRT7, and some of them, espe-
cially SIRT1, have been shown to play pivotal roles in the
regulation of aging, longevity, or in the pathogenesis of
age-related metabolic diseases, such as type 2 diabetes
[16–18]. The expressions of sirtuin families have also been
observed in the kidneys, and recently SIRT1 has been
shown to mediate a protective role of calorie restriction
(CR) in the progression of the aging kidney [19]. These
observations suggest the possibility that mammalian sirtu-
ins are a candidate for conferring susceptibility to diabetic
nephropathy.
In order to test this hypothesis, we focused on genes
encoding mammalian sirtuins as candidate genes for dia-
betic nephropathy and investigated the association between
SNPs within the SIRT genes and diabetic nephropathy in
Japanese subjects with type 2 diabetes.
Materials and methods
Subjects, DNA preparation
Study 1
DNA samples were obtained from the peripheral blood of
patients with type 2 diabetes who regularly visited the
outpatient clinic at Shiga University of Medical Science,
Tokyo Women’s Medical University, Juntendo University,
Kawasaki Medical School, Iwate Medical University,
Toride Kyodo Hospital, Kawai Clinic, Osaka City General
Hospital, Chiba Tokushukai Hospital, or Osaka Rosai
Hospital. Diabetes was diagnosed according to the World
Health Organization criteria. Type 2 diabetes was clinically
deﬁned as a disease with gradual adult onset. Subjects who
tested positive for anti-glutamic acid decarboxylase anti-
bodies and those diagnosed with mitochondrial disease
(mitochondrial myopathy, encephalopathy, lactic acidosis,
and stroke-like episodes (MELAS)) or maturity onset dia-
betes of the young were not included. The patients were
divided into 2 groups: (1) the nephropathy group (n = 754,
age 60.1 ± 0.4, diabetes duration 19.3 ± 0.4, body mass
index (BMI) 23.7 ± 0.2, mean ± SE) comprised patients
with diabetic retinopathy and overt nephropathy indicated
by a urinary albumin excretion rate (AER) C200 lg/min or
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123a urinary albumin/creatinine ratio (ACR) C300 mg/g cre-
atinine (Cr), and (2) the control group (n = 558, age
62.4 ± 0.5, diabetes duration 15.3 ± 0.4, BMI 23.6 ± 0.2)
comprised patients who had diabetic retinopathy but no
evidence of renal dysfunction (i.e. AER \20 lg/min or
ACR\30 mg/g Cr). The AER or ACR were measured at
least twice for each patient.
Study 2
We selected diabetic nephropathy patients and control
patients among the subjects enrolled in the BioBank Japan.
Nephropathy cases were deﬁned as patients with type 2
diabetes having both overt diabetic nephropathy and
diabetic retinopathy (n = 449, age 64.7 ± 0.4, BMI
23.5 ± 0.2). The control subjects were patients with type 2
diabetes who had diabetic retinopathy and normoalbu-
minuria (n = 965, age 64.8 ± 0.3, BMI 23.8 ± 0.1).
Study 3
Patients with type 2 diabetes who regularly visited Tokai
University Hospital or its afﬁliated hospitals were enrolled
in this study. All the nephropathy patients (n = 300, age
64.4 ± 0.6, diabetes duration 21.9 ± 0.9, BMI 22.1 ± 0.2,
mean ± SE) were receiving chronic hemodialysis therapy,
and the control patients (n = 224, age 65.0 ± 0.7, diabetes
duration 16.3 ± 0.4, BMI 23.4 ± 0.3, mean ± SE) inclu-
ded those with normoalbuminuria as determined by at least
2 measurements of urinary ACR and with diabetes
for[10 years.
All the patients participating in this study provided
written informed consent, and the study protocol was
approved by the ethics committees of RIKEN Yokohama
Institute and of each participating institution.
The clinical characteristics of the subjects are shown in
Supplementary Table 1.
SNP genotyping
We searched the HapMap database (http://hapmap.
ncbi.nlm.nih.gov/) for SNPs within the genes encoding
sirtuin families, and selected 55 SNPs (39 tagging SNPs)
for genotyping; 11 in SIRT1 (rs12778366, rs3740051,
rs2236318, rs2236319, rs10823108, rs10997868, rs2273
773, rs3818292, rs3818291, rs4746720, rs10823116), 7 in
SIRT2 (rs1001413, rs892034, rs2015, rs2241703, rs208
2435, rs11575003, rs2053071), 15 in SIRT3 (rs11246002,
Table 1 Association between SNPs in SIRT1 and diabetic nephropathy
Allele frequencies (nephropathy case-control)
Proteinuria ESRD Combined
Study 1 Study 2 P OR (95% CI) Study 3 P OR (95% CI)
SNP
rs12778366
a T[C 0.111/0.103 0.125/0.124 0.672 1.04 (0.86–1.26) 0.101/0.119 0.981 0.998 (0.84–1.18)
rs3740051
a A[G 0.291/0.277 0.316/0.301 0.299 1.07 (0.94–1.22) 0.310/0.274 0.138 1.09 (0.97–1.23)
rs2236318
a T[A 0.121/0.129 0.099/0.111 0.327 0.91 (0.75–1.10) 0.106/0.119 0.236 0.90 (0.76–1.07)
rs2236319 A[G 0.339/0.317 0.358/0.339 0.165 1.09 (0.96–1.24) 0.349/0.300 0.048 1.12 (1.00–1.26)
rs10823108 G[A 0.335/0.318 0.357/0.335 0.169 1.09 (0.96–1.24) 0.351/0.302 0.049 1.12 (1.00–1.26)
rs10997868
a C[A 0.187/0.184 0.187/0.174 0.520 1.05 (0.90–1.23) 0.180/0.173 0.482 1.05 (0.91–1.21)
rs2273773 T[C 0.339/0.325 0.361/0.347 0.325 1.07 (0.94–1.21) 0.353/0.306 0.113 1.10 (0.98–1.23)
rs3818292 A[G 0.336/0.317 0.360/0.335 0.134 1.10 (0.97–1.25) 0.352/0.306 0.042 1.13 (1.00–1.26)
rs3818291 G[A 0.111/0.101 0.127/0.129 0.650 1.04 (0.87–1.26) 0.101/0.124 0.927 0.99 (0.84–1.17)
rs4746720
a T[C 0.366/0.394 0.331/0.364 0.041 0.88 (0.77–0.99) 0.367/0.400 0.021 0.88 (0.78–0.98)
rs10823116
a A[G 0.446/0.442 0.441/0.448 0.905 0.99 (0.88–1.12) 0.459/0.394 0.428 1.05 (0.94–1.16)
Haplotype
TGTGACCGGTG 0.294/0.279 0.316/0.300 0.250 1.08 (0.95–1.23) 0.315/0.273 0.095 1.10 (0.98–1.24)
TATAGCTAGCA 0.255/0.273 0.251/0.252 0.464 0.95 (0.83–1.09) 0.253/0.304 0.143 0.91 (0.81–1.03)
CATAGCTAATA 0.112/0.103 0.124/0.129 0.817 1.02 (0.85–1.23) 0.100/0.119 0.841 0.98 (0.83–1.16)
TAAAGATAGTA 0.123/0.128 0.104/0.112 0.484 0.94 (0.78–1.13) 0.105/0.122 0.319 0.92 (0.78–1.08)
TATAGCTAGCG 0.109/0.123 0.085/0.111 0.037 0.81 (0.67–0.99) 0.113/0.099 0.117 0.87 (0.73–1.03)
TATAGATAGTA 0.065/0.055 0.078/0.059 0.051 1.27 (0.998–1.61) 0.077/0.053 0.016 1.31 (1.05–1.62)
TATGACCGGTG 0.042/0.039 0.040/0.036 0.57 1.09 (0.81–1.48) 0.036/0.028 0.421 1.12 (0.85–1.48)
a Tag SNPs
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123rs2293168, rs3216, rs10081, rs511744, rs6598074,
rs4758633, rs11246007, rs3782117, rs3782116, rs3782115,
rs1023430, rs12576565, rs536715, rs3829998), 7 in SIRT4
(rs6490288, rs7298516, rs3847968, rs12424555, rs713
7625, rs2261612, rs2070873), 11 in SIRT5 (rs2804923,
rs9382227, rs2804916, rs2804918, rs9370232, rs4712047,
rs3734674, rs11751539, rs3757261, rs2253217, rs284
1514), and 4 in SIRT6 (rs350852, rs7246235, rs107251,
rs350844). We could not identify any conﬁrmed SNPs
within SIRT7 in the Japanese population. The genotyping
of these SNPs was performed by using multiplex poly-
merase chain reaction (PCR)-invader assays, as described
previously [7–10].
Statistical analyses
We tested the genotype distributions for Hardy–Weinberg
equilibrium (HWE) proportions by using the chi-squared
test. We analyzed the differences between the case-con-
trol groups in terms of the distribution of genotypes with
the Cochran–Armitage trend test. The analyses for haplo-
type structures within each gene were performed using
Haploview software version 4.1 [20]. A combined meta-
analysis was performed using the Mantel–Haenszel pro-
cedure with a ﬁxed effects model after testing for
heterogeneity.
Results
Among the 55 SNPs examined, genotype distributions of 3
SNPs, rs12576565 in SIRT3, and rs2804923 and rs2841514
in SIRT 5, showed signiﬁcant deviation from HWE pro-
portion in control groups (P\0.01, Supplementary
Table 2), and these 3 SNPs were excluded from the asso-
ciation study. As shown in Table 1, 8 out of 11 SNPs in
SIRT1 showed a directionally consistent association with
diabetic nephropathy in all 3 studies, although individual
associations were not signiﬁcant (P[0.05, Supplementary
Table 2). In a combined meta-analysis, we could identify a
nominally signiﬁcant association between rs4746720 and
proteinuria, and between 4 SNPs, rs2236319, rs10823108,
rs3818292, rs4746720, and combined phenotypes (pro-
teinuria ? ESRD, P\0.05). Subsequent haplotype anal-
ysis revealed that the 11 SNPs formed one haplotype block
(Fig. 1), and 7 common haplotypes covered [99% of the
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Fig. 1 Position of the 11 SNPs
in SIRT1, and pair-wise linkage
disequilibrium coefﬁcients (r
2)
among 11 SNPs in the present
Japanese population
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123present Japanese population. Among them one haplotype
had a stronger association with diabetic nephropathy than
single SNPs alone (P = 0.016, odds ratio (OR) 1.31 95%
conﬁdence interval (CI) 1.05–1.62]. Any SNPs or haplo-
types in SIRT2–6 were not associated with diabetic
nephropathy in the combined analysis (Tables 2, 3, 4, 5, 6),
although there was an association between 3 SNPs
(rs4712047, rs3734674, rs3757261) in SIRT5 and diabetic
nephropathy in the study 2 population (Supplementary
Table 2). To validate the association between SIRT1 and
diabetic nephropathy, we examined another 195 cases
(overt proteinuria) and 264 controls registered in the Bio-
Bank Japan (study 4). As shown in Table 7, most SNPs
showed a consistent association with those in the original
ﬁnding, and the association of the haplotype was
strengthened further (P = 0.0028, OR 1.36, 95% CI
1.11–1.66). We further examined the association between
SIRT1 SNPs and microalbuminuria in studies 1 and 2, but
could not identify a signiﬁcant association (Supplementary
Table 3), suggesting SIRT1 SNPs might contribute to the
progression of nephropathy rather than its onset in patients
with type 2 diabetes.
Discussion
In the present study, we identiﬁed that SNPs within SIRT1
were nominally associated with susceptibility to diabetic
nephropathy. We also identiﬁed one haplotype consisting
of the 11 SNPs in SIRT1 had a stronger association with
diabetic nephropathy than single SNPs alone.
SIRT1 encodes a member of NAD(?)-dependent histone
deacetylase, involved in various nuclear events such as
transcription, DNA replication, and DNA repair. Cumula-
tive evidence during the past decade has demonstrated that
SIRT1 plays an important role not only in the regulation of
aging and longevity, but also in the development and/or
progression of age-associated metabolic diseases, such as
type 2 diabetes. SIRT1 activation is considered to be a key
mediator for favorable effects on lifespan or on metabolic
activity in animals under calorie restriction (CR) [21–24].
Recently, Kume et al. [19] reported that mice under 40%
CR were protected from the development of glomerular
sclerosis in aging mice kidneys through increasing mito-
chondrial biogenesis caused by sirt1 activation. From these
observations, it is suggested that SIRT1 has a pivotal role
Table 2 Association between SNPs in SIRT2 and diabetic nephropathy
Allele frequencies (nephropathy case-control)
Proteinuria ESRD Combined
Study 1 Study 2 P OR (95% CI) Study 3 P OR (95% CI)
SNP
rs1001413
a G[A 0.381/0.359 0.353/0.361 0.594 1.03 (0.91–1.17) 0.342/0.389 0.837 0.99 (0.88–1.11)
rs892034
a C[T 0.193/0.166 0.180/0.169 0.099 1.14 (0.98–1.34) 0.164/0.194 0.352 1.07 (0.93–1.23)
rs2015
a A[C 0.398/0.400 0.389/0.406 0.550 0.96 (0.85–1.09) 0.384/0.391 0.522 0.96 (0.86–1.08)
rs2241703
a G[A 0.235/0.226 0.222/0.215 0.534 1.05 (0.91–1.21) 0.219/0.208 0.453 1.05 (0.92–1.20)
rs2082435
a C[G 0.247/0.262 0.260/0.270 0.365 0.94 (0.82–1.08) 0.256/0.231 0.678 0.97 (0.86–1.10)
rs11575003
a T[C 0.118/0.115 0.126/0.132 0.886 0.99 (0.82–1.18) 0.132/0.119 0.887 1.01 (0.86–1.19)
rs2053071
a G[C 0.377/0.398 0.384/0.396 0.260 0.93 (0.82–1.05) 0.426/0.402 0.506 0.96 (0.86–1.08)
Haplotype
Block 1
CCGG 0.243/0.258 0.245/0.268 0.136 0.90 (0.79–1.03) 0.254/0.226 0.366 0.95 (0.84–1.07)
CAAC 0.231/0.222 0.227/0.216 0.438 1.06 (0.92–1.22) 0.218/0.204 0.347 1.06 (0.94–1.21)
CAGC 0.179/0.212 0.207/0.206 0.186 0.91 (0.78–1.05) 0.232/0.205 0.477 0.95 (0.84–1.09)
TAGC 0.191/0.165 0.191/0.169 0.037 1.18 (1.01–1.37) 0.164/0.197 0.196 1.10 (0.95–1.26)
CCGC 0.154/0.142 0.127/0.140 0.993 0.999 (0.84–1.18) 0.130/0.164 0.497 0.95 (0.81–1.04)
Block 2
TG 0.620/0.597 0.614/0.599 0.191 1.08 (0.96–1.22) 0.568/0.585 0.346 1.05 (0.95–1.17)
TC 0.262/0.288 0.256/0.270 0.142 0.91 (0.79–1.03) 0.300/0.295 0.121 0.91 (0.81–1.02)
CC 0.114/0.110 0.126/0.127 0.850 1.02 (0.85–1.22) 0.127/0.109 0.586 1.05 (0.89–1.23)
Block 1; rs892034, rs2015, rs2241703, rs2082435
Block 2; rs11575003, rs2053071
a Tag SNPs
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123in the pathogenesis of aging-related metabolic diseases,
such as type 2 diabetes or glomerulosclerosis, and a genetic
difference in SIRT1 activity among individuals, if it is
present, may contribute to conferring susceptibility to these
diseases.
In the present study, we identiﬁed that SNPs within
SIRT1 were nominally associated with diabetic nephropa-
thy, whereas SNPs in other sirtuin families did not show
any association with diabetic nephropathy. Combining the
present ﬁnding with a previous report, SIRT1 may be
considered a good new candidate for diabetic nephropathy,
although, the role of sirtuin families other than SIRT1 in
age-related metabolic diseases has not been well evaluated.
The mechanism by which the SIRT1 polymorphism con-
tributes to conferring susceptibility to diabetic nephropathy
remains to be elucidated. Since SIRT1 could affect various
metabolic activities, the effects of SIRT1 polymorphisms
on susceptibility to diabetic nephropathy might be medi-
ated by differences in the metabolic state among individ-
uals, including glycemic control, obesity, blood pressure,
Table 3 Association between SNPs in SIRT3 and diabetic nephropathy
Allele frequencies (nephropathy case-control)
Proteinuria ESRD Combined
Study 1 Study 2 P OR (95% CI) Study 3 P OR (95% CI)
SNP
rs11246002
a G[A 0.137/0.123 0.152/0.137 0.169 1.13 (0.95–1.34) 0.122/0.110 0.138 1.13 (0.96–1.32)
rs2293168 G[A 0.356/0.362 0.385/0.402 0.440 0.95 (0.84–1.08) 0.400/0.372 0.776 0.98 (0.88–1.10)
rs3216 C[G 0.172/0.168 0.160/0.155 0.742 1.03 (0.87–1.21) 0.152/0.192 0.655 0.97 (0.84–1.12)
rs10081
a A[G 0.507/0.515 0.464/0.463 0.805 1.02 (0.90–1.15) 0.460/0.514 0.338 0.95 (0.85–1.06)
rs511744
a C[T 0.488/0.482 0.469/0.485 0.778 0.98 (0.87–1.11) 0.491/0.487 0.853 0.99 (0.89–1.10)
rs6598074 T[C 0.164/0.161 0.126/0.135 0.797 0.98 (0.82–1.16) 0.154/0.144 0.963 0.996 (0.86–1.16)
rs4758633
a G[A 0.347/0.355 0.288/0.294 0.599 0.97 (0.85–1.10) 0.319/0.349 0.360 0.94 (0.84–1.06)
rs11246007
a C[T 0.143/0.155 0.149/0.152 0.471 0.94 (0.79–1.11) 0.142/0.143 0.512 0.95 (0.82–1.11)
rs3782117
a A[G 0.168/0.171 0.160/0.153 0.843 1.02 (0.86–1.20) 0.152/0.193 0.544 0.96 (0.83–1.11)
rs3782116
a G[A 0.307/0.294 0.278/0.272 0.507 1.05 (0.92–1.19) 0.292/0.268 0.333 1.06 (0.94–1.20)
rs3782115
a C[T 0.283/0.283 0.265/0.257 0.785 1.02 (0.89–1.17) 0.263/0.241 0.964 1.04 (0.92–1.17)
rs1023430
a A[G 0.291/0.302 0.325/0.307 0.849 1.01 (0.89–1.15) 0.285/0.275 0.743 1.02 (0.91–1.15)
rs536715
a G[A 0.367/0.367 0.395/0.406 0.736 0.98 (0.86–1.11) 0.404/0.389 0.939 0.996 (0.89–1.11)
rs3829998
a G[A 0.167/0.167 0.124/0.139 0.529 0.95 (0.80–1.12) 0.160/0.153 0.674 0.97 (0.83–1.13)
Haplotype
Block 1
GACT 0.354/0.362 0.378/0.398 0.342 0.94 (0.83–1.06) 0.403/0.377 0.635 0.97 (0.87–1.09)
GGCC 0.335/0.346 0.310/0.309 0.700 0.98 (0.86–1.11) 0.317/0.321 0.688 0.97 (0.87–1.09)
GGGC 0.172/0.168 0.159/0.154 0.688 1.03 (0.88–1.21) 0.151/0.192 0.678 0.97 (0.84–1.12)
AGCT 0.138/0.123 0.151/0.137 0.171 1.27 (0.95–1.34) 0.124/0.110 0.127 1.13 (0.97–1.11)
Block 2
TGGA 0.519/0.511 0.560/0.556 0.710 1.02 (0.91–1.15) 0.550/0.521 0.462 1.04 (0.94–1.16)
TAGG 0.171/0.169 0.158/0.153 0.765 1.02 (0.87–1.20) 0.151/0.192 0.622 0.96 (0.84–1.11)
TGAA 0.143/0.155 0.150/0.152 0.49 0.94 (0.80–1.11) 0.142/0.142 0.540 0.95 (0.82–1.11)
CAGA 0.167/0.164 0.131/0.136 0.952 0.99 (0.84–1.17) 0.157/0.146 0.868 0.95 (0.82–1.11)
Block 3
AAG 0.364/0.363 0.383/0.402 0.547 0.96 (0.85–1.09) 0.403/0.384 0.779 0.98 (0.88–1.10)
GGG 0.287/0.297 0.320/0.303 0.801 1.02 (0.89–1.16) 0.281/0.265 0.640 1.03 (0.92–1.15)
AGG 0.177/0.170 0.157/0.152 0.618 1.04 (0.89–1.22) 0.154/0.191 0.809 0.98 (0.85–1.13)
AGA 0.168/0.166 0.133/0.140 0.856 0.98 (0.84–1.16) 0.158/0.152 0.967 0.997 (0.86–1.16)
Block 1; rs11246002, rs2293168, rs3216, rs10081
Block 2; rs6598074, rs4758633, rs11246007, rs3782117
Block 3; rs1023430, rs536715, rs3829998
a Tag SNPs
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123Table 4 Association between SNPs in SIRT4 and diabetic nephropathy
Allele frequencies (nephropathy case-control)
Proteinuria ESRD Combined
Study 1 Study 2 P OR (95% CI) Study 3 P OR (95% CI)
SNP
rs6490288 G[C 0.068/0.076 0.076/0.077 0.574 0.94 (0.74–1.18) 0.080/0.066 0.880 0.98 (0.80–1.21)
rs7298516
a T[G 0.009/0.009 0.008/0.011 0.608 0.85 (0.46–1.58) 0.017/0.016 0.714 0.91 (0.54–1.53)
rs3847968
a C[T 0.187/0.184 0.187/0.174 0.450 0.91 (0.71–1.16) 0.180/0.173 0.806 1.03 (0.82–1.28)
rs12424555 C[T 0.059/0.069 0.065/0.069 0.366 0.89 (0.70–1.14) 0.071/0.046 0.912 0.99 (0.79–1.23)
rs7137625
a C[T 0.057/0.040 0.058/0.056 0.141 1.23 (0.94–1.60) 0.045/0.063 0.435 1.10 (0.87–1.40)
rs2261612 A[G 0.473/0.484 0.457/0.476 0.338 0.94 (0.84–1.06) 0.476/0.459 0.532 0.97 (0.87–1.08)
rs2070873
a T[G 0.469/0.476 0.457/0.474 0.443 0.95 (0.85–1.08) 0.480/0.468 0.600 0.97 (0.87–1.08)
Haplotype
Block 1
CCCAT 0.527/0.518 0.546/0.520 0.245 1.07 (0.95–1.21) 0.517/0.532 0.400 1.05 (0.94–1.16)
CCCGG 0.350/0.368 0.326/0.348 0.154 0.91 (0.81–1.03) 0.360/0.342 0.305 0.94 (0.84–1.05)
TTCGG 0.058/0.067 0.065/0.062 0.695 0.95 (0.75–1.21) 0.067/0.052 0.932 1.01 (0.81–1.26)
CCTGG 0.056/0.039 0.056/0.056 0.181 1.20 (0.92–1.56) 0.046/0.063 0.501 1.08 (0.86–1.38)
Block 1; rs3847968, rs12424555, rs7137625, rs2261612, rs2070873
a Tag SNPs
Table 5 Association between SNPs in SIRT5 and diabetic nephropathy
Allele frequencies (nephropathy case-control)
Proteinuria Combined
Study 1 Study 2 P OR (95% CI) Study 3 P OR (95% CI)
SNP
rs9382227
a G[T 0.188/0.196 0.218/0.192 0.494 1.05 (0.91–1.22) 0.198/0.210 0.688 1.03 (0.90–1.18)
rs2804916
a T[C 0.170/0.166 0.157/0.163 0.921 0.99 (0.84–1.17) 0.138/0.135 0.971 0.997 (0.86–1.16)
rs2804918
a A[G 0.345/0.357 0.352/0.333 0.847 1.01 (0.89–1.15) 0.318/0.321 0.896 1.01 (0.90–1.13)
rs9370232
a G[C 0.361/0.370 0.358/0.362 0.640 0.97 (0.86–1.10) 0.357/0.346 0.797 0.99 (0.88–1.10)
rs4712047
a G[A 0.494/0.477 0.448/0.505 0.221 0.93 (0.82–1.05) 0.456/0.457 0.269 0.94 (0.84–1.05)
rs3734674 G[A 0.158/0.171 0.191/0.149 0.252 1.10 (0.93–1.29) 0.176/0.188 0.416 1.06 (0.92–1.23)
rs11751539
a A[T 0.309/0.320 0.302/0.312 0.476 0.95 (0.84–1.09) 0.315/0.276 0.955 0.997 (0.87–1.12)
rs3757261
a G[A 0.155/0.165 0.184/0.139 0.159 1.12 (0.95–1.32) 0.168/0.174 0.252 1.09 (0.94–1.26)
rs2253217
a A[G 0.063/0.071 0.056/0.068 0.210 0.85 (0.67–1.09) 0.045/0.061 0.111 0.83 (0.67–1.04)
Haplotype
Block 1
GT 0.641/0.637 0.629/0.645 0.666 0.97 (0.86–1.10) 0.665/0.655 0.796 0.99 (0.88–1.10)
TT 0.189/0.196 0.215/0.192 0.519 1.05 (0.91–1.22) 0.198/0.210 0.711 1.03 (0.90–1.17)
GC 0.171/0.167 0.156/0.163 0.086 0.87 (0.74–1.02) 0.137/0.135 0.949 0.995 (0.86–1.15)
Block 2
GAGA 0.471/0.442 0.446/0.478 0.904 0.99 (0.88–1.12) 0.468/0.491 0.674 0.98 (0.88–1.09)
GTGA 0.311/0.320 0.313/0.312 0.758 0.98 (0.86–1.11) 0.313/0.272 0.734 1.02 (0.91–1.14)
AAAA 0.154/0.166 0.184/0.139 0.150 1.12 (0.96–1.32) 0.169/0.174 0.239 1.09 (0.94–1.26)
GAGG 0.061/0.067 0.054/0.061 0.353 0.89 (0.70–1.14) 0.042/0.050 0.280 0.88 (0.70–1.11)
Block 1; rs9382227, rs2804916
Block 2; rs3734674, rs11751539, rs3757261, rs2253217, rs2841514
a Tag SNPs
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123etc. We then examined the association between SNPs in
SIRT1 and BMI, hemoglobin A1c (HbA1c), fasting plasma
glucose, or systolic blood pressure in the present subjects
with type 2 diabetes, but we could not observe any asso-
ciation between the SIRT1 SNPs and those quantitative
traits (P[0.05, Supplementary Table 4). In contrast to our
present ﬁnding, SNPs within the SIRT1, rs7895833 and
rs1467568, were shown to be signiﬁcantly associated with
BMI in Dutch populations [25]. We did not examine those
SNPs, but the present study includes an SNP in high
linkage disequilibrium (LD) to these 2 SNPs (rs10997
868; r
2 = 1 and 0.64 to rs1467568 and rs7895833,
Table 6 Association between SNPs in SIRT6 and diabetic nephropathy
Allele frequencies (nephropathy case-control)
Proteinuria ESRD Combined
Study 1 Study 2 P OR (95% CI) Study 3 P OR (95% CI)
SNP
rs350852
a T[C 0.313/0.338 0.313/0.303 0.545 0.96 (0.84–1.09) 0.324/0.348 0.367 0.95 (0.84–1.06)
rs7246235
a T[G 0.185/0.186 0.168/0.209 0.110 0.88 (0.75–1.03) 0.202/0.164 0.447 0.95 (0.82–1.09)
rs107251
a C[T 0.296/0.315 0.305/0.291 0.841 0.99 (0.87–1.12) 0.323/0.328 0.799 0.98 (0.88–1.11)
rs350844 G[A 0.304/0.322 0.309/0.291 0.936 0.99 (0.87–1.13) 0.336/0.347 0.819 0.99 (0.88–1.11)
Haplotype
Block 1
TCG 0.516/0.499 0.529/0.500 0.122 1.10 (0.98–1.24) 0.517/0.532 0.342 1.05 (0.95–1.17)
TTA 0.299/0.318 0.303/0.291 0.776 0.98 (0.86–1.12) 0.360/0.342 0.713 0.98 (0.87–1.10)
GCG 0.185/0.183 0.168/0.209 0.100 0.88 (0.76–1.02) 0.067/0.052 0.433 0.95 (0.83–1.09)
Block 1; rs7246235, rs107251, rs350844
a Tag SNPs
Table 7 Replication study for the association between SNPs in SIRT1 and diabetic nephropathy
Allele frequencies
(nephropathy case-control)
Proteinuria (study 1, 2, 4) Proteinuria ? ESRD (study 1, 2, 3, 4)
Study 4 P OR (95% CI) P OR (95% CI)
SNP
rs12778366
a T[C 0.089/0.131 0.676 0.96 (0.81–1.15) 0.448 0.94 (0.80–1.10)
rs3740051
a A[G 0.311/0.291 0.226 1.08 (0.96–1.21) 0.106 1.09 (0.98–1.22)
rs2236318
a T[A 0.113/0.116 0.350 0.92 (0.78–1.09) 0.257 0.91 (0.78–1.07)
rs2236319 A[G 0.360/0.344 0.142 1.09 (0.97–1.22) 0.044 1.12 (1.00–1.24)
rs10823108 G[A 0.358/0.337 0.127 1.09 (0.97–1.23) 0.038 1.12 (1.01–1.24)
rs10997868
a C[A 0.181/0.175 0.490 1.05 (0.91–1.21) 0.456 1.05 (0.92–1.20)
rs2273773 T[C 0.364/0.342 0.239 1.07 (0.95–1.20) 0.085 1.10 (0.99–1.22)
rs3818292 A[G 0.358/0.344 0.120 1.10 (0.98–1.23) 0.040 1.12 (1.01–1.24)
rs3818291 G[A 0.090/0.132 0.696 0.97 (0.81–1.15) 0.412 0.94 (0.80–1.10)
rs4746720
a T[C 0.371/0.361 0.084 0.90 (0.81–1.01) 0.044 0.90 (0.81–0.997)
rs10823116
a A[G 0.453/0.450 0.939 0.996 (0.89–1.11) 0.446 1.04 (0.94–1.15)
Haplotype
TGTGACCGGTG 0.306/0.297 0.240 1.07 (0.95–1.21) 0.098 1.09 (0.98–1.22)
TATAGCTAGCA 0.269/0.243 0.809 0.96 (0.87–1.11) 0.336 0.95 (0.85–1.06)
CATAGCTAATA 0.105/0.129 0.741 0.97 (0.82–1.15) 0.496 0.95 (0.81–1.10)
TAAAGATAGTA 0.122/0.116 0.621 0.96 (0.81–1.13) 0.430 0.94 (0.80–1.09)
TATAGCTAGCG 0.095/0.112 0.022 0.82 (0.69–0.97) 0.071 0.86 (0.74–1.01)
TATAGATAGTA 0.072/0.059 0.0091 1.34 (1.07–1.66) 0.0028 1.36 (1.11–1.66)
TATGACCGGTG 0.031/0.044 0.942 1.01 (0.77–1.33) 0.746 1.04 (0.81–1.35)
a Tag SNPs
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123respectively). Interestingly, there is a dramatic difference
in the frequency of the reported protected allele (A allele of
rs1467568) between European and Japanese populations
(0.25 in the European population vs. 0.841 in the Japanese
population, HapMap database, http://www.ncbi.nlm.nih.gov/
projects/SNP/snp_ref.cgi?rs=1467568). Since rs10997868
was not associated with either BMI or susceptibility to the
disease, ethnic differences may contribute to the discrep-
ancy between the Dutch and Japanese populations, and the
contribution of SIRT1 SNPs to BMI, if it is present, is
considered very minor in the Japanese population. It has
been also reported that SNPs in SIRT1 were associated with
energy expenditure in a small number of Finnish healthy
nondiabetic offspring of patients with type 2 diabetes [23].
The alleles associated with higher energy expenditure,
supposed to be favorable alleles for glucose metabolism,
are G for rs3740051, G for rs2236319, and C for
rs2273773, respectively; although these alleles increase the
risk of diabetic nephropathy in the present Japanese pop-
ulation. From these observations, we speculate that the
effects of SIRT1 gene polymorphisms on diabetic
nephropathy are independent of these metabolic parame-
ters; however, there are limitations to the present cross-
sectional study and further longitudinal prospective studies
are required to obtain a precise conclusion. The association
between individual SIRT1 SNPs and diabetic nephropathy
did not attain statistically signiﬁcant levels after correction
for multiple-testing errors, and a haplotype consisting of 11
SIRT1 SNPs had a stronger association with the disease,
suggesting the existence of other true causal variations
within this locus. In addition, since nephropathy cases in
the present study were at a more advanced stages of dia-
betic nephropathy, the ﬁndings on SNPs and the haplotype
within SIRT1 may be applicable mainly to advanced dia-
betic nephropathy. Therefore, further extensive analyses
for this locus, re-sequencing, dense LD mapping, or further
conﬁrmation studies are also required to link the SIRT1
locus to the genetic susceptibility of diabetic nephropathy
as a whole.
In conclusion, we found that the SNPs and a haplotype
within SIRT1 were nominally associated with susceptibility
to diabetic nephropathy in four independent Japanese case–
control studies. The present data suggest that SIRT1 may be
a good candidate for diabetic nephropathy, although the
association should be evaluated further in independent
studies.
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